Skip to main content
. Author manuscript; available in PMC: 2014 Apr 1.
Published in final edited form as: Cancer Res. 2013 Jan 30;73(7):2127–2138. doi: 10.1158/0008-5472.CAN-12-4184

FIGURE 4. CXCR5-targeted delivery of CpG-ODN blocks tBregs and activates B cells eliciting cytolytic CD8+ T cells.

FIGURE 4

(A,B) Ex vivo generation of murine tBregs was done in the absence or presence of various TLR ligands (5 µg/ml of ssRNA40; 10 µg/ml of Pam3CSK4 or FSL-1; 5 µg/ml of LPS; 1 µg/ml ODN1826 PS (CpG) and control CpG K) or 10 µg/ml anti-IgM. After 48h, cells were stained for CD20 expression (A) and evaluated for the ability to suppress proliferation of CD3+ T cells stimulated with anti-CD3 Ab (B). FITC- labeled CpG is better uptaken by tBregs when coupled with BLC-arp (continuous line, C), as compared with free CpG (broken line, C). Shaded area is for untreated control cells (C). BLC-arp/CpG (3 µg/ml ODN1826 PS) blocks activity of murine tBregs in vitro, at the same extent as free CpG, as shown by the inability to inhibit proliferation of CFSE-labeled CD3+ T cells (D). Controls were B cells treated with BAFF (B-Mock) and untreated tBregs.